Jonathan Brammer, MD

Dr. Brammer on FDA Approval of Brentuximab Vedotin in CTCL

November 10th 2017

Jonathan Brammer, MD, hematologist, Department of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the FDA approval of brentuximab vedotin (Adcetris) for the treatment of patients with cutaneous T-cell lymphoma (CTCL).